Sanctura XR

Indevus enters licensing pact with Madaus
7th November 2006
By Staff Writer
Indevus Pharmaceuticals has licensed the rights to sell Sanctura XR, the once-daily formulation of trospium chloride for overactive bladder to Madaus, in certain territories outside the US.
Madaus has marketed trospium chloride throughout Europe for over 20 years.

"We believe the position Madaus holds in the European market offers us the best opportunity to successfully commercialize Sanctura XR outside the US," said Glenn Cooper, CEO of Indevus. "This agreement increases the economic opportunity for Indevus as Madaus currently markets trospium chloride through much of the world either directly or through co-promotion or distribution partners."

Under the terms of the agreement, Madaus has the right to sell Sanctura XR outside the US except in Canada, Japan, Korea and China, where Indevus and Madaus will share equally in the economics. Madaus will pay Indevus a royalty on net sales and will purchase Sanctura XR from Indevus at cost plus a manufacturing margin based on units sold in the Madaus territories.

Separately the company said that Madaus has agreed to waive its rights under the original licensing agreement with Indevus to manufacture Sanctura XR in the US. Indevus will sell Sanctura XR to its partner Esprit Pharma for the US market.

In June and July 2006, the company reported positive results from the two phase III trials for Sanctura XR in overactive bladder

Analyze the Commercial Potential for Sanctura XR, A Recently-Approved Next-Generation Overactive Bladder Agent
Business Wire, Sept 27, 2006
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c42806) has announced the addition of the new report from Datamonitor "Financial Markets Research: Indevus Pharmaceuticals Sanctura XR - Last-to-market Entrant Unlikely to Make an Impact in Crowded OAB Market" to their offering.

The lack of differentiation between overactive bladder agents has led manufacturers to turn to large-scale marketing efforts in an attempt to gain market share. Given the relatively small marketing capabilities of IDEV and Esprit, they may have difficulty penetrating high-prescribing urology and primary care practices compared to its larger rivals, thus slowing Sanctura XRs near-term potential.

Related Results: sanctura xr
Indevus Initiates Phase III
Clinical Program for SANCTURA... More
Video
Motorsports video - klx crf xr...
More
Scope of this title:

This title analyzes the commercial potential for IDEVs Sanctura XR, a recently-approved next-generation OAB agent. For this report we interviewed twenty-four urologists regarding trends in the treatment of OAB and the potential role of next-generation Sanctura XR

Highlights of this title include:

Based on the data from the Phase II trial, we anticipate that once-daily Sanctura XR will demonstrate a safety and efficacy profile comparable to the original twice-daily Sanctura formulation and support its FDA approval in mid/late 2007.

Interviewed physicians indicated that all currently marketed OAB products have comparable safety and efficacy profiles and, as the last once-daily OAB option to come to market, if approved, Sanctura XR would not dramatically impact their OAB prescribing habits given the crowded OAB market.

http://www.thestreet.com/s/10-biotec.../10362958.html


Indevus Pharmaceuticals (IDEV - Cramer's Take - Stockpickr - Rating)
Drug/indication: Sanctura XR for overactive bladder
FDA decision date: Aug. 13

Clinical data suggests that Sanctura XR is the best drug in the overactive bladder class, which is a billion-dollar-plus market and growing. (You can't watch network news without seeing multiple ads for overactive bladder drugs.)

But therein lies the catch. Tiny Indevus and its not-so-much-bigger marketing partner Esprit Pharma have to figure out a way to convince doctors to prescribe Sanctura XR against Big Pharma competitors with very deep marketing pockets.

http://videoplayer.thestreet.com/?cl...=1185285194703

Cramer was speaking at the Annex and he starts talking about Indevus at 3:01 minutes.

Isn't it weird that the Indevus reps. have not received samples of Sanctura BID. Hum..................

Could it be easier for Espirt to manage ONLY THEIR inventory before the divest the drug to someone else?

Could it be that they are dumb enough to think that the INDV reps. are not worthy of samples?

Could it be that Indevus is not launching XR and that is why we have not recieved samples?

I am going with the first choice...........it is easier to manage only one sales force with samples prior to divesting the rights to XR. Think about it. It's only 3 FREAKING WEEKS BEFORE APPROVAL and we have not heard A word about a copromotion partnership.